File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: ITRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma

TitleITRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma
Authors
KeywordsBioinformatics
ITRAQ
Proteomics
Renal cell carcinoma
Tumor marker
Issue Date2016
Citation
BioScience Trends, 2016, v. 10, n. 3, p. 210-219 How to Cite?
AbstractEarly detection is the key to improve the prognosis of kidney cancer. This study profiled and identified differentially expressed serum proteins in stage T1a renal cell carcinoma (RCC) using isobaric tags for relative and absolute quantification (iTRAQ)-based mass spectrometry. A total amount of 99 serum samples including 29 patients with ccRCC, 24 patients with a benign kidney mass, 28 patients with another type of urological tumor (20 cases of transitional cell carcinoma and 8 cases of prostate cancer or a male genital tumor), and 18 healthy controls were subjected to iTRAQ-based mass spectrometry. ProteinPilot software was used to identify the differentially expressed serum proteins in RCC compared to the other three populations. Hierarchical clustering analysis according to The Cancer Genome Atlas (TCGA) RCC database was then performed as the cross-platform validation. Immunohistochemistry was performed to verify the expression of selected proteins in tissue samples from these subjects. iTRAQ identified 27 differentially expressed serum proteins in the RCC patients, and 11 of these proteins were cross validated in RCC tissues from the TCGA database. The expression of C1QC, C1QB, S100A8, S100A9, ceruplasmin, and lumican was verified and associated with the tumor stage and/or grade. There were 27 differentially expressed proteins in early-stage RCC identified by iTRAQ; among them, the expression of C1QC, C1QB, S100A8, S100A9, ceruplasmin, and lumican were associated with the tumor stage and/or grade. Further studies are needed to confirm these data for their use as biomarkers for the early detection of RCC.
Persistent Identifierhttp://hdl.handle.net/10722/314390
ISSN
2023 Impact Factor: 5.7
2023 SCImago Journal Rankings: 0.876
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhang, Limin-
dc.contributor.authorJiang, Haowen-
dc.contributor.authorXu, Gang-
dc.contributor.authorChu, Nan-
dc.contributor.authorXu, Ningxing-
dc.contributor.authorWen, Hui-
dc.contributor.authorGu, Bin-
dc.contributor.authorLiu, Jun-
dc.contributor.authorMao, Shanghua-
dc.contributor.authorNa, Rong-
dc.contributor.authorJing, Yan-
dc.contributor.authorDing, Qiang-
dc.contributor.authorZhang, Yuanfang-
dc.contributor.authorWang, Ling-
dc.date.accessioned2022-07-20T12:03:55Z-
dc.date.available2022-07-20T12:03:55Z-
dc.date.issued2016-
dc.identifier.citationBioScience Trends, 2016, v. 10, n. 3, p. 210-219-
dc.identifier.issn1881-7815-
dc.identifier.urihttp://hdl.handle.net/10722/314390-
dc.description.abstractEarly detection is the key to improve the prognosis of kidney cancer. This study profiled and identified differentially expressed serum proteins in stage T1a renal cell carcinoma (RCC) using isobaric tags for relative and absolute quantification (iTRAQ)-based mass spectrometry. A total amount of 99 serum samples including 29 patients with ccRCC, 24 patients with a benign kidney mass, 28 patients with another type of urological tumor (20 cases of transitional cell carcinoma and 8 cases of prostate cancer or a male genital tumor), and 18 healthy controls were subjected to iTRAQ-based mass spectrometry. ProteinPilot software was used to identify the differentially expressed serum proteins in RCC compared to the other three populations. Hierarchical clustering analysis according to The Cancer Genome Atlas (TCGA) RCC database was then performed as the cross-platform validation. Immunohistochemistry was performed to verify the expression of selected proteins in tissue samples from these subjects. iTRAQ identified 27 differentially expressed serum proteins in the RCC patients, and 11 of these proteins were cross validated in RCC tissues from the TCGA database. The expression of C1QC, C1QB, S100A8, S100A9, ceruplasmin, and lumican was verified and associated with the tumor stage and/or grade. There were 27 differentially expressed proteins in early-stage RCC identified by iTRAQ; among them, the expression of C1QC, C1QB, S100A8, S100A9, ceruplasmin, and lumican were associated with the tumor stage and/or grade. Further studies are needed to confirm these data for their use as biomarkers for the early detection of RCC.-
dc.languageeng-
dc.relation.ispartofBioScience Trends-
dc.subjectBioinformatics-
dc.subjectITRAQ-
dc.subjectProteomics-
dc.subjectRenal cell carcinoma-
dc.subjectTumor marker-
dc.titleITRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.5582/bst.2016.01055-
dc.identifier.pmid27319973-
dc.identifier.scopuseid_2-s2.0-84980322497-
dc.identifier.volume10-
dc.identifier.issue3-
dc.identifier.spage210-
dc.identifier.epage219-
dc.identifier.eissn1881-7823-
dc.identifier.isiWOS:000379253700007-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats